75%Confidence
0Views
FDASource
2026-03-18Date
Summary
Midodrine hydrochloride tablet recall due to defective blister packaging presents patient safety risks and potential liability for The Harvard Drug Group. This packaging failure could trigger increased FDA scrutiny on blister packaging standards across the industry, particularly for cardiovascular medications.
Actionable: Verify packaging integrity for all blister-packed medications in inventory, especially those from similar packaging facilities.
AI Confidence: 75%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now